Coeptis Therapeutics Holdings (Nasdaq: COEP) and Z Squared Inc. announced a definitive merger agreement on April 25, 2025, to create the world’s largest publicly traded dogecoin-focused mining company. As part of the transaction, Coeptis will spin off its biopharmaceutical operations.

Coeptis Therapeutics Holdings（NASDAQ：COEP）和Z Squared Inc.于2025年4月25日宣布了一项确定的合并协议，以创建全球最大的以Dogecoin为中心的最大公开交易的矿业公司。作为交易的一部分，Coeptis将脱离其生物药物操作。

Upon completion of the merger, Z Squared will become a wholly owned subsidiary of Coeptis. In exchange for 9,000 U.S.-based dogecoin (DOGE) mining machines, shareholders of Z Squared will receive equity in Coeptis.

合并完成后，Z平方将成为Coeptis的全资子公司。为了换取9,000个总部位于美国的Dogecoin（Doge）采矿机，Z Squared的股东将获得Coeptis的股权。

The transaction, approved by both boards of directors, is subject to regulatory clearances, Nasdaq listing compliance, and shareholder approval. Closure is anticipated in Q3 2025, with the combined entity rebranding as Z Squared, Inc. and trading on Nasdaq.

两家董事会批准的交易均受监管许可，纳斯达克上市合规性和股东批准的约束。预计第3季度的第3季度将关闭，合并后的实体将Z Squared，Inc。和在纳斯达克交易的交易。

Z Squared executives David Halabu and Michelle Burke will helm the merged company as CEO and COO, respectively. Coeptis CEO Dave Mehalick will step down from the board post-closure. Halabu, founder of Group 10 Capital Management, highlighted the merger's aim to provide investors with concentrated exposure to dogecoin's $27 billion market cap.

Z Squared高管David Halabu和Michelle Burke将分别担任合并后的公司担任首席执行官和COO。 Coeptis首席执行官戴夫·梅哈里克（Dave Mehalick）将在关闭后的董事会上辞职。第10组资本管理的创始人Halabu强调了合并的目的，目的是为投资者提供集中在Dogecoin的270亿美元市场上限上。

The new company will dedicate its efforts to mining dogecoin and collecting proof-of-work blockchain rewards. Mehalick elaborated that shareholders will have the opportunity to participate in dogecoin markets while retaining an interest in the spun-off biopharma operations, which will continue independently.

这家新公司将致力于开采Dogecoin并收集工作证明区块链奖励。 Mehalick阐述了股东将有机会参与Dogecoin市场，同时保留对旋转生物制药业务的兴趣，这将继续独立。

Coeptis' biopharmaceutical divisions, developing cell therapies for cancer and infectious diseases, will continue operating within the spun-off entity. Its technology division, featuring AI and automation tools, will remain with the merged company.

Coeptis的生物药物分裂，开发针对癌症和传染病的细胞疗法，将继续在旋转实体中运作。它的技术部门具有AI和自动化工具，将保留在合并的公司中。

Z Squared, specializing in the mining of DOGE and litecoin (LTC), aims to capitalize on the burgeoning altcoin mining sector. Further transaction details, including leadership economic interests and merger agreement terms, will be filed with the U.S. Securities and Exchange Commission (SEC).

Z Squared专门研究Doge和Litecoin（LTC）的开采，旨在利用新兴的Altcoin矿业领域。进一步的交易详细信息，包括领导经济利益和合并协议条款，将提交美国证券交易委员会（SEC）。

Investors are directed to relevant filings with the SEC for complete information on leadership economic interests and merger terms.

投资者被指向与SEC的相关文件，以获取有关领导经济利益和合并条款的完整信息。